Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target

Reuters01-22

Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target

Emerging Growth Research has released a Flash Research Update on Immuron Limited (Nasdaq: IMRN), maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan® immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129903) on January 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605460193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605460193","market":"us","top_or_hot":-1,"title":"Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has released a Flash Research Update on Immuron Limited (Nasdaq: IMRN), maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan® immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129903) on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has released a Flash Research Update on Immuron Limited (Nasdaq: IMRN), maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan® immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129903) on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2t9Qry:1","article_id":"2605460193","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605460193","pubTimestamp":1769079651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emerging Growth Research has released a Flash Research Update on Immuron Limited , maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","IMC.AU":"IMMURON LTD"},"translate_title":"Emerging Growth Research维持Immuron Limited的买入-延长评级，目标价为3.50美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMC.AU":0.9},"content_text":"Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target\n    \n\n        Emerging Growth Research has released a Flash Research Update on Immuron Limited (Nasdaq: IMRN), maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan® immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129903) on January 22, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605460193","isCrawlerRequest":true}